Transarterial chemoembolization and bland embolization for hepatocellular carcinoma.
Transarterial chemoembolization (TACE) is the first line treatment for patients with intermediate stage hepatocellular carcinoma but is also increasingly being used for patients on the transplant waiting list to prevent further tumor growth. Despite its widespread use, TACE remains an unstandardized procedure, with variation in type and size of embolizing particles, type and dose of chemotherapy and interval between therapies. Existing evidence from randomized controlled trials suggest that bland transarterial embolization (TAE) has the same efficacy with TACE. In the current article, we review the use of TACE and TAE for hepatocellular carcinoma and we focus on the evidence for their use.
Emmanuel A Tsochatzis, Evangelia Fatourou, James O'Beirne, Andrew K Burroughs, Sheila Sherlock Liver Centre, Royal Free Hospital and UCL Institute of Liver and Digestive Health, London NW3 2QG, United Kingdom.
Emmanuel A
EA
Tsochatzis
Emmanuel A Tsochatzis, Evangelia Fatourou, James O'Beirne, Andrew K Burroughs, Sheila Sherlock Liver Centre, Royal Free Hospital and UCL Institute of Liver and Digestive Health, London NW3 2QG, United Kingdom.
Evangelia
E
Fatourou
Emmanuel A Tsochatzis, Evangelia Fatourou, James O'Beirne, Andrew K Burroughs, Sheila Sherlock Liver Centre, Royal Free Hospital and UCL Institute of Liver and Digestive Health, London NW3 2QG, United Kingdom.
James
J
O'Beirne
Emmanuel A Tsochatzis, Evangelia Fatourou, James O'Beirne, Andrew K Burroughs, Sheila Sherlock Liver Centre, Royal Free Hospital and UCL Institute of Liver and Digestive Health, London NW3 2QG, United Kingdom.
Tim
T
Meyer
Emmanuel A Tsochatzis, Evangelia Fatourou, James O'Beirne, Andrew K Burroughs, Sheila Sherlock Liver Centre, Royal Free Hospital and UCL Institute of Liver and Digestive Health, London NW3 2QG, United Kingdom.
Andrew K
AK
Burroughs
D000792:Angiography; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001158:Arteries / Q000473:pathology; D006528:Carcinoma, Hepatocellular / Q000628:therapy*; D016461:Chemoembolization, Therapeutic / Q000379:methods*; D003131:Combined Modality Therapy; D004621:Embolization, Therapeutic / Q000379:methods*; D006801:Humans; D008113:Liver Neoplasms / Q000628:therapy*; D020360:Neoadjuvant Therapy / Q000379:methods; D011169:Portal Vein / Q000473:pathology; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome; D020246:Venous Thrombosis / Q000628:therapy; D014850:Waiting Lists
D000970:Antineoplastic Agents
Cirrhosis; Embolization; Hepatocellular carcinoma; Mortality; Prognosis; Transarterial chemoembolization; Transarterial embolization